about
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)European union standards for tuberculosis careARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cyclePrognostic factors for lung function in systemic sclerosis: prospective study of 105 cases.Increased Rho-kinase expression and activity and pulmonary endothelial dysfunction in smokers with normal lung function.Clopidogrel protects from cell apoptosis and oxidative damage in a mouse model of renal ischaemia-reperfusion injury.Induction of stress proteins by tobacco smoke in human monocytes: modulation by antioxidants.High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation.Study of Exhaled Nitric Oxide in Subjects with Suspected Obstructive Sleep Apnea: A Pilot Study in Vietnam.Role of vascular endothelial growth factor in prostate cancer.Congenital diaphragmatic hernia: current status and review of the literature.Study of nasal exhaled nitric oxide levels in diagnosis of allergic rhinitis in subjects with and without asthma.Role of Rho-kinase and its inhibitors in pulmonary hypertension.The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review).Bronchial effects of alpha 2-adrenoceptor agonists and of other antihypertensive agents in asthma.Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis.Serum levels of vascular endothelial growth factor in patients undergoing prostate biopsy for suspicion of prostate cancer.MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation.Nitrogen monoxide and carbon monoxide transfer interpretation: state of the art.A European Respiratory Society technical standard: exhaled biomarkers in lung disease.Fasudil inhibits prostate cancer-induced angiogenesis in vitro.Utilising exhaled nitric oxide information to enhance diagnosis and therapy of respiratory disease - current evidence for clinical practice and proposals to improve the methodology.Protective effects of hsp70 in inflammation.Bronchial blood flow and microvascular permeability in the pathophysiology of asthma.The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure.Integrated care pathways for airway diseases (AIRWAYS-ICPs).Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).The editors' farewell and a confident look back to the future.Role of tyrosine phosphatase in the modulation of pulmonary vascular tone.Severe pulmonary hypertension: walking through new paths to revisit an old field.Altered myosin isoform expression in rat skeletal muscles induced by a changed thyroid state.Nitric oxide inhibits spleen cell proliferative response after burn injury by inducing cytostasis, apoptosis, and necrosis of activated T lymphocytes: role of the guanylate cyclase.The hepatopulmonary syndrome: NO way out?High alveolar concentration of nitric oxide is associated with alveolitis in scleroderma.Inhaled NO prevents hyperoxia-induced white matter damage in neonatal rats.Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.Prognostic value of six minute walk test in cystic fibrosis adults.The European Respiratory Journal makes COPD a priority.Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.Ventilation-induced pulmonary vasodilatation in lambs with congenital diaphragmatic hernia is modulated by nitric oxide.
P50
Q26740215-9C4C985B-D9BC-46F6-A035-160D912E3A62Q26823223-D4F9CA7E-1007-4B1D-B9DA-D7401211B486Q28355722-27C98A1E-B9A0-4DD1-BB0C-71B0A15DBDADQ34018132-072A226B-4000-4344-9E64-726009DB50E0Q34022680-967D4573-F01C-48A1-83B2-71D00A4E1B93Q34027137-79C1529C-4B36-4F05-98BA-A3E658803F19Q35087060-289E0021-9A99-49FE-9186-BFE0B0FB261BQ36524695-9D454E44-5F35-441C-A1A4-605BA95F8704Q36533522-9C1A7A68-C554-4263-BA64-68ABDAA5A512Q36563885-5C73F918-38DA-44D3-A517-078C6C0AFDC6Q37357125-94F5A4BC-3F00-4D72-BBF6-945CAF455A18Q37722660-B53325F6-F52E-40DE-B015-5FDACC274469Q38069345-F9FE8446-454B-4D43-9820-111E2B21DD0EQ38257530-0499525C-B3DF-4044-9BF5-19E5115493FFQ38364974-F71361E0-EFC1-4EF6-9668-8197778D8A2BQ38394278-DBD22361-28CB-40EE-AFAC-A30B132299D3Q38441133-00952FD6-D2BE-4B0A-A536-B048EF7A73B4Q38543189-42F7E369-41F3-46AC-8EC9-CE89D939333CQ38635797-0028385E-86B8-46C5-B390-D252A1E1003BQ38690466-FD6C58E5-1B43-4B1E-A38F-20BC9E48D996Q38946275-6ED4A58B-BAA1-45F8-9FD0-8862F05B2235Q39079947-8F3B9EDB-612A-434B-92FD-F8DFF545B55EQ40648752-13A711F1-03AC-4D8B-B825-224F31012A91Q41188295-76B43A94-B640-4869-B553-9C405B1787B8Q41685120-9ECD0840-BD37-4B06-90F4-0AF87CDB4DD1Q42210687-3D05D3B5-2325-4DE3-BD62-14369652EBEDQ42320566-9C0F20E1-A8CE-448C-B83C-BE465C120983Q43457624-969DDE28-4034-4E54-9B1D-74866C228909Q43949784-768BA86B-D786-4207-A473-BE6BD66DC2A0Q44162526-070A89EC-84A4-4A8C-863E-39FF6BAAC7EDQ44188635-CCD431A7-FCE1-47ED-B858-094860978654Q44437870-05A4E82E-1AE2-4511-958C-FC8E52141337Q44920344-5EFB4032-E5DE-42B7-9E4E-75DCA48BFB4CQ44966241-96AD25BF-15B2-4E84-B1E6-7B8C0B6AD3F0Q45020107-7C2A636C-3792-4822-8A0F-090191A5D206Q45965532-8E0FA321-7D5C-4DD3-A085-61E3A8C88259Q45983416-C5E11415-2E7A-440F-9364-66E55E7A5EBAQ46014245-0829FBDF-9746-45E3-9026-70C74F4112A3Q46064623-9082BF1F-E80C-489F-9C3F-4F7D7E44D189Q46419330-B0FE247E-606E-4362-B9D7-128DE9F2A617
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anh Tuan Dinh-Xuan
@ast
Anh Tuan Dinh-Xuan
@en
Anh Tuan Dinh-Xuan
@es
Anh Tuan Dinh-Xuan
@nl
type
label
Anh Tuan Dinh-Xuan
@ast
Anh Tuan Dinh-Xuan
@en
Anh Tuan Dinh-Xuan
@es
Anh Tuan Dinh-Xuan
@nl
prefLabel
Anh Tuan Dinh-Xuan
@ast
Anh Tuan Dinh-Xuan
@en
Anh Tuan Dinh-Xuan
@es
Anh Tuan Dinh-Xuan
@nl
P1053
A-9691-2008
P106
P108
P1153
57198203849
7005824392
P31
P3829
P496
0000-0001-8651-5176
P569
2000-01-01T00:00:00Z